Muhammad Salman Ali Ashraf – FDA 483, May 16, 2019
An FDA inspection of Muhammad Salman Ali Ashraf, a clinical investigator in Springfield, OH, revealed significant deficiencies in the conduct of a clinical study. Observations included a lapse in IRB approval, failure to obtain informed consent from a majority of subjects, and multiple deviations from the investigational plan regarding screening labs, inclusion criteria, and adverse event reporting. These findings indicate serious non-compliance with regulatory requirements for human subject protection and clinical trial conduct.
ID · 18e219e6-f80e-4f2b-84ac-d3ec9c59d226
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.